Comparative Pharmacology
Head-to-head clinical analysis: EXSEL versus LUZU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSEL versus LUZU.
EXSEL vs LUZU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
1-2 mg orally once daily; maximum dose 2 mg/day.
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
None Documented
None Documented
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route.
Category C
Category C
Topical Antifungal
Topical Antifungal